Asia-Pacific Cancer Biomarkers Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 12.50 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Asia-Pacific Cancer Biomarkers Market Analysis
The Asia-Pacific cancer biomarkers market is expected to register a CAGR of nearly 12.5% during the forecast period.
- Due to the COVID-19 pandemic, the number of visits to hospitals and diagnostic centers for cancer care decreased during the early pandemic in the Asia-Pacific region, reducing the demand for cancer biomarkers.
- For instance, according to an article published by BMC Cancer in December 2022, a study was conducted in Japan which showed that COVID-19 had prolonged collateral effects on cancer care in Japan, including examination, diagnosis, and surgery, with significant effects on breast cancer, among others. Thus, due to the COVID-19 pandemic, the cancer biomarkers market was significantly impacted during the initial pandemic. However, as the pandemic has subsided, cancer diagnosis and treatment are going back to pre-pandemic levels, so the Asia-Pacific cancer biomarkers market is expected to have stable growth during the forecast period of the study.
- The significant factors contributing to the growth of the Asia-Pacific cancer biomarkers market are the rising prevalence of cancer, the increasing research activities, and the growing usage of biomarkers in drug development.
- The rising prevalence of cancer across the region is the primary factor driving the market growth, as it will increase the usage of cancer biomarkers for diagnosis purposes. For instance, as per the report published by PubMed Central in March 2022, China has a high incidence of cancers. In 2022 it was expected that there would be approximately 4.8 million new cancer cases in China, the most common being lung cancer. Thus, the high prevalence of cancer in the country is expected to boost market growth.
- Moreover, according to a report published by the Indian Council of Medical Research (ICMR) in 2021, Leukemia accounted for nearly half of all childhood cancers in both genders in the 0-14 years age group in India; it had a prevalence of 46.4% in boys and 44.3% in girls in 2021. The other common childhood cancer in boys was lymphoma (16.4%); in girls, it was a malignant bone tumor (8.9%). Moreover, according to the data published by the Indian Council of Medical Research-National Cancer Registry Programme (ICMR-NCRP) in March 2023, the number of cancer cases in India is projected to increase from 1.46 million in 2022 to 1.57 million in 2025. Hence, the high burden of various cancers is expected to increase the adoption of cancer biomarkers during the forecast period of the study.
- Additionally, according to an article published by the Institute of Cancer Research in July 2022, biomarkers are an important way of directing treatment to those cancer patients who will benefit most and therefore are likely to increase the cost-effectiveness of treatment. They can be used to develop new targeted therapies and immunotherapies for cancer. Thus, the rising research activities and the increasing use of cancer biomarkers in drug development are expected to boost the market growth.
- Hence, the factors above, such as the rising prevalence of cancer and the increasing usage of biomarkers in drug development for cancer, are expected to boost market growth. However, the high cost of diagnosis and reimbursement issues are expected to impede market growth.
Asia-Pacific Cancer Biomarkers Market Trends
Breast Cancer is Expected to Grow with a Significant CAGR in the Market Over the Forecast Period
- Breast cancer occurs when cells in a patient's breast grow and divide in an uncontrolled way, creating a mass of tissue called a tumor. Breast cancer is considered one of the most prevalent cancers compared to other types of cancer and is also treatable. The increasing awareness about breast cancer and the rising prevalence of the disease are some of the major factors due to which this segment will grow more rapidly as compared to others.
- The rising prevalence of breast cancer around the region is expected to boost segment growth. For instance, according to the bi-annual report published by the Indian Council of Medical Research (ICMR) in December 2022, the national average of cancer cases for 2022 in India was 100.4 per 100,000, with a large number of women (an estimated 105.4 per 100,000) being diagnosed with breast cancer. The source also stated an estimated 182,000 people are living with breast cancer in India, which is expected to reach 250,000 by 2030. Thus, due to the country's high burden of breast cancer, the demand for cancer biomarkers is expected to increase, which will drive the growth of the studied segment.
- Similarly, according to an article published by Cancer Research and Treatment in March 2022, it is estimated that 28,142 new breast cancer cases were noted in South Korea in 2022, out of which 28,032 were female and 110 were male. The source also stated that the age-standardized incidence of breast cancer in South Korea was 33.1 out of 100,000 in 2022. Thus, the high burden of breast cancer in South Korea is expected to boost the segment's growth.
- Moreover, according to an article published by PubMed in January 2022, a plasma biomarker panel was developed which was effective in differentiating breast cancer from benign diseases of the breast in South Asian women, and it could help as a complementary diagnostic tool for breast cancer. Hence, the factors above, such as the rising prevalence of breast cancer and the increasing usage of biomarkers in the early detection of breast cancer, are expected to boost market growth.
Japan is Expected to Hold a Significant Market Share Over the Forecast Period
- Japan is expected to hold a significant market share over the forecast period due to factors such as the rising prevalence of cancer in the country, the increasing launch of technologically advanced products, the rising geriatric population, and the growing research and development regarding cancer in the country.
- For instance, according to the data published by National Cancer Center Japan in June 2022, an estimated 1,019,000 new cases of cancer were diagnosed in Japan in 2022, out of which colon and rectum cancer, stomach cancer, lung/trachea cancer, prostate cancer, and breast cancer were the most prevalent. Thus, the country's high cancer burden is expected to boost the usage of cancer biomarkers during the forecast period of the study.
- Moreover, According to an article published by Multidisciplinary Digital Publishing Institute (MDPI) in April 2022, it has been observed that in Japan, cancer precision medicine initiatives such as SCRUM-Japan (solid tumors) and MASTER KEY project function as screening platforms that helps in identifying cancer patients with mutations who may be eligible to participate in ongoing clinical trials. The accumulated genomic and clinical data in these initiatives often contribute to a growing clinical-genomic database from which novel biomarkers are identified.
- Thus, the increasing research activities on cancer biomarkers in Japan are also expected to boost the market growth in the country. Additionally, as cancer is primarily diagnosed in older adults, the rising geriatric population in the country is also expected to boost market growth. Thus, the factors mentioned above, such as the increasing aging population and the rising prevalence of cancer, are expected to boost market growth.
Asia-Pacific Cancer Biomarkers Industry Overview
The Asia-Pacific cancer biomarkers market is fragmented due to the presence of several market players. These players are focusing on R&D, market expansions, partnerships, and mergers to experience stable growth. Some of the key players in the Asia-Pacific cancer biomarkers market are Abbott Laboratories Inc., Thermo Fisher Scientific, Agilent Technologies, Biomerieux SA, and Celera Corporation (Quest Diagnostics), among others.
Asia-Pacific Cancer Biomarkers Market Leaders
-
Abbott Laboratories Inc.
-
Biomerieux
-
F. Hoffmann-La Roche Ltd
-
Thermo Fisher Scientific
-
Qiagen NV
*Disclaimer: Major Players sorted in no particular order
Asia-Pacific Cancer Biomarkers Market News
- October 2022: The Garvan Institute of Medical Research in Australia discovered a new biomarker for prostate cancer that could lead to better diagnosis and treatment for men with the aggressive form of this disease.
- February 2022: The University of South Australia used novel biomarkers to decode metastatic breast cancer. They found a connection between aggressive breast cancer cells and the dual CXCR4-CCR7 cell surface protein complexes.
Asia-Pacific Cancer Biomarkers Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Cancer
4.2.2 Increasing Research Activities and Growing Usage of Biomarkers in Drug Development
4.3 Market Restraints
4.3.1 High Cost of Diagnosis
4.3.2 Reimbursement Issues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Cancer Type
5.1.1 Prostate Cancer
5.1.2 Breast Cancer
5.1.3 Lung Cancer
5.1.4 Colorectal Cancer
5.1.5 Cervical Cancer
5.1.6 Other Cancer Type
5.2 By Type of Biomarker
5.2.1 Protein Biomarkers
5.2.2 Genetic Biomarkers
5.2.3 Other Types of Biomarkers
5.3 By Profiling Technology
5.3.1 OMICS Technologies
5.3.2 Imaging Technologies
5.3.3 Immunoassays
5.3.4 Cytogenetics
5.4 Geography
5.4.1 China
5.4.2 Japan
5.4.3 India
5.4.4 Australia
5.4.5 South Korea
5.4.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories Inc.
6.1.2 Thermo Fisher Scientific
6.1.3 Agilent Technologies
6.1.4 Biomerieux SA
6.1.5 Celera Corporation (Quest Diagnostics)
6.1.6 Hologic Inc.
6.1.7 Illumina Inc.
6.1.8 Merck & Co Inc.
6.1.9 Qiagen NV
6.1.10 F. Hoffmann-La Roche Ltd
6.1.11 ASURAGEN, INC.
6.1.12 BioVision Inc. (Abcam)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Asia-Pacific Cancer Biomarkers Industry Segmentation
As per the scope of the report, a biomarker may be used to see how well the body responds to a treatment for a disease or condition. Thus, a cancer biomarker pertains to any biomarker that fits the aforementioned definition, but only for cancer and no other disease. Cancer biomarkers are more than just a signal of the disease and have many roles in fighting cancer.
The Asia-Pacific cancer biomarkers market is segmented by cancer type (prostate cancer, breast cancer, lung cancer, colorectal cancer, cervical cancer, and other cancer types), type of biomarker (protein biomarkers, genetic biomarkers, and other types of biomarkers), profiling technology (OMICS technologies, imaging technologies, immunoassays, and cytogenetics), and geography (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific).
The report offers the value (in USD million) for the above segments.
| By Cancer Type | |
| Prostate Cancer | |
| Breast Cancer | |
| Lung Cancer | |
| Colorectal Cancer | |
| Cervical Cancer | |
| Other Cancer Type |
| By Type of Biomarker | |
| Protein Biomarkers | |
| Genetic Biomarkers | |
| Other Types of Biomarkers |
| By Profiling Technology | |
| OMICS Technologies | |
| Imaging Technologies | |
| Immunoassays | |
| Cytogenetics |
| Geography | |
| China | |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific |
Asia-Pacific Cancer Biomarkers Market Research FAQs
What is the current Asia-Pacific Cancer Biomarkers Market size?
The Asia-Pacific Cancer Biomarkers Market is projected to register a CAGR of 12.5% during the forecast period (2024-2029)
Who are the key players in Asia-Pacific Cancer Biomarkers Market?
Abbott Laboratories Inc., Biomerieux, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific and Qiagen NV are the major companies operating in the Asia-Pacific Cancer Biomarkers Market.
What years does this Asia-Pacific Cancer Biomarkers Market cover?
The report covers the Asia-Pacific Cancer Biomarkers Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Cancer Biomarkers Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
APAC Cancer Biomarkers Industry Report
Statistics for the 2024 APAC Cancer Biomarkers market share, size and revenue growth rate, created by 糖心vlog传媒鈩� Industry Reports. APAC Cancer Biomarkers analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
